STOPPING GLP-1 MEDICATION: HOW TO KEEP THE WEIGHT OFF

Stopping GLP-1 medication usually brings weight back: a year after stopping semaglutide in the STEP 1 trial extension, people had regained about two-thirds of the weight they lost. The good news comes from newer trials. Staying on a lower dose, or switching to a daily pill, kept most of the loss off for at least a year. If you are on GLP-1 weight loss at Hartwater Wellness or anywhere else, plan the next phase before you stop.
By Elaine Burris, APRN, FNP-C, Wellness Nurse Practitioner, Hartwater Wellness
Medically reviewed by Scott Bradley Burris, MD, Medical Director and board-certified anesthesiologist. Reviewed December 2026.
THE SHORT ANSWER
Stopping completely: most people regain most of the weight within a year, and blood pressure, cholesterol, and blood sugar gains drift back too.
Staying on full dose: the strongest protection. In SURMOUNT-4, people who stayed on tirzepatide lost another 5.5%.
Stepping down: dropping tirzepatide to 5 mg kept much more weight off than stopping (SURMOUNT-MAINTAIN).
Switching to a pill: people who moved from Wegovy or Zepbound to daily Foundayo kept about three-quarters of their loss at one year (ATTAIN-MAINTAIN).
Tracking: weight, waist, an InBody scan, and a metabolic lab panel show whether you are holding ground, before the scale makes it obvious.
WHAT THE TRIALS SHOW ABOUT STOPPING GLP-1 MEDICATION
Four randomized trials tested what happens after the weight-loss phase. The table summarizes them.
The pattern is consistent across both drugs: stopping GLP-1 treatment brings the weight back for most people, while staying on some form of it holds most of the loss. In the STEP 1 extension, the improvements in blood pressure, cholesterol, and blood sugar also faded toward their starting levels after semaglutide stopped. The authors concluded that obesity behaves as a chronic condition and that ongoing treatment is usually needed to keep the health benefits.
WHY THE WEIGHT COMES BACK
GLP-1 medications quiet hunger and slow stomach emptying while you take them. When the medication leaves your system, appetite usually returns to where it was. Meanwhile your body, now smaller, burns fewer calories than it did at your starting weight. That combination makes regain the default. Willpower has little to do with it.
Muscle matters here too. Strength training and enough protein during treatment help you keep the muscle that supports your metabolism. Our post on muscle loss on GLP-1 covers both in detail. Those habits carry over after the medication stops.
YOUR OPTIONS FOR MAINTENANCE
Stay on your current dose
Staying on the dose that got you to goal has the strongest evidence. In SURMOUNT-4, people who continued tirzepatide for another year lost an additional 5.5%. Of that group, 89.5% kept at least 80% of their earlier loss. For many patients, treating weight like blood pressure, with a medication taken long term, is the most reliable plan.
Step down to a lower dose
In SURMOUNT-MAINTAIN, people who had reached their maximum tolerated tirzepatide dose and then dropped to 5 mg ended the trial 16.6% below their starting weight. Those who stayed on the full dose were 21.9% below, and those switched to placebo 9.9% below. A step-down keeps much of the benefit for some people. Responses vary, so we step down gradually and watch the numbers closely. At Hartwater, compounded medications are priced flat at any dose, so a lower dose does not lower the monthly price.
Switch to a daily pill
In ATTAIN-MAINTAIN, people who switched from weekly Zepbound or Wegovy to daily orforglipron (sold as Foundayo) kept about 75% and 79% of their loss at one year, compared with 49% and 38% on placebo. The Wegovy pill (oral semaglutide) is also approved to help maintain weight loss. Both pills cost less than the injections at the top dose: as of October 28, 2026, Foundayo ran $149 to $349 a month and the Wegovy pill $149 to $299 a month by dose. Our 2026 GLP-1 cost guide lists every price with its source. Several manufacturer prices were scheduled for review after December 31, 2026.
Stop, with a plan
Some patients stop because of cost, side effects, pregnancy plans, or preference. Gradual tapering has not been tested in a large randomized trial, so we treat a taper as a careful experiment: reduce in steps, keep protein and strength training in place, and agree in advance on the weight or lab change that would prompt restarting.
THE NUMBERS THAT SHOW WHETHER YOU ARE HOLDING GROUND
You cannot optimize what you have not measured. After a dose change or a stop, these numbers show early whether the plan is holding:
Weight and waist, checked at home weekly, so a trend shows within a month.
InBody 970S body composition, which separates fat regain from water and shows whether visceral fat is creeping back.
HbA1c, fasting glucose, and fasting insulin (HOMA-IR), the blood sugar markers that improved during treatment.
Lipid panel, including triglycerides and, on our Cardiometabolic Optimization Panel, ApoB.
Liver enzymes (ALT and AST) and blood pressure, which often improved with weight loss.
On treatment, our GLP-1 patients have lab monitoring at months 3, 6, and 12, then yearly, with InBody scans about every 8 weeks. After a stop or step-down, we recommend repeating the same labs and a scan at about three months. The longevity lab panels page lists the panels; the Cardiometabolic Optimization Panel is $599. Hartwater Wellness is a cash-pay practice; HSA and FSA accepted.
WHAT IS COMING
Two newer medications may change maintenance planning, and neither is available yet:
Retatrutide (Lilly), a weekly injection that acts on three hormone receptors. In the TRIUMPH-1 trial, announced May 21, 2026, the 12 mg dose produced 28.3% average weight loss at 80 weeks. It is investigational and not FDA-approved.
CagriSema (Novo Nordisk), a weekly combination of semaglutide and cagrilintide. Novo Nordisk filed for FDA approval in December 2025. In February 2026, its head-to-head trial against tirzepatide did not show it was as effective. As of this writing, the FDA had not announced a decision.
Neither has published maintenance data yet. For now, the four trials above are the evidence.
FREQUENTLY ASKED QUESTIONS
What happens when you stop semaglutide?
Appetite usually returns over the following weeks. In the STEP 1 extension, people regained about two-thirds of their lost weight within a year of stopping, and most heart and metabolic improvements faded toward baseline. Results vary, and some people keep more of their loss than others.
Do you have to take a GLP-1 forever?
Many people need some form of ongoing treatment to keep the weight and health benefits, much like blood pressure medication. That can mean a lower dose or a daily pill, which trials show can hold most of the loss. Some people stop successfully with close monitoring and strong habits.
Can you taper off a GLP-1 instead of stopping all at once?
Yes, and a step-down is a reasonable option to discuss. The best evidence is for stepping tirzepatide down to 5 mg, which kept more weight off than stopping. No large trial has tested a full taper to zero, so we monitor weight, body composition, and labs at each step.
How much does it cost to stay on a GLP-1 for maintenance?
As of October 28, 2026, the lowest-cost brand options were the daily pills, at $149 to $349 a month by dose. At Hartwater, compounded semaglutide is $299 a month and compounded tirzepatide is $499 a month at any dose, with care included. Compounded medications are not FDA-approved.
SCHEDULE A CONSULTATION
If you are thinking about stopping a GLP-1 or have already stopped and see the scale moving, a consultation is the place to build a maintenance plan around your labs and body composition. Hartwater Wellness is a physician-led practice at 7200 West University Drive, Suite 170, in McKinney, serving Frisco, Allen, Prosper, Plano, Celina, and Collin County. Schedule online or call (469) 678-8748.
SOURCES
Wilding JPH et al., Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension, Diabetes, Obesity and Metabolism 2022;24(8):1553-1564: https://doi.org/10.1111/dom.14725
Aronne LJ et al., Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: the SURMOUNT-4 Randomized Clinical Trial, JAMA 2024;331(1):38-48: https://doi.org/10.1001/jama.2023.24945
Horn DB et al., Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN), The Lancet 2026;407:2305-2318: https://doi.org/10.1016/S0140-6736(26)00656-2
Aronne LJ et al., Orforglipron for maintenance of body weight reduction: the ATTAIN-MAINTAIN trial, Nature Medicine 2026;32:2679-2687: https://doi.org/10.1038/s41591-026-04386-7
Novo Nordisk, "Wegovy pill approved in the US as first oral GLP-1 for weight management" (December 22, 2025): https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916472
Eli Lilly, "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial" (May 21, 2026): https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
Novo Nordisk, "Novo Nordisk files for FDA approval of CagriSema" (December 2025): https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645868.html
CNBC, "What's next for Novo Nordisk's next-generation obesity drug CagriSema after trial miss" (February 24, 2026): https://www.cnbc.com/2026/02/24/healthy-returns-whats-next-for-novo-nordisks-obesity-drug-cagrisema.html
NovoCare Pharmacy, Wegovy self-pay offer, checked October 28, 2026: https://www.novocare.com/pharmacy/wegovy/offer.html
Eli Lilly, Foundayo coverage and savings, checked October 28, 2026: https://foundayo.lilly.com/coverage-savings
Hartwater Wellness, GLP-1 Weight Loss (prices, lab and scan schedule), checked October 28, 2026: https://www.hartwaterwellness.com/glp-1-therapy-mckinney-tx
Hartwater Wellness, Longevity Lab Panels (Cardiometabolic Optimization Panel), checked October 28, 2026: https://www.hartwaterwellness.com/longevity-lab-panels-mckinney-tx
.png)



